Turn Therapeutics Inc.
Turn Therapeutics Inc. (TTRX): 1 pipeline candidate · ~21 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
20.7 months
D/E 2.05 · 0% dilution
Lead: Phase 2
1 candidate
N/A
N/A
A transparent, data-derived signal for Turn Therapeutics Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$191.2M
Cash
$11.2M
Quarterly Burn
$1.6M
Runway
20.7 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| gx-03 | Phase 2 |
Frequently asked questions
How many drug candidates are in Turn Therapeutics Inc.'s pipeline?
Turn Therapeutics Inc. (TTRX) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Turn Therapeutics Inc.'s lead drug candidate?
Turn Therapeutics Inc.'s most advanced tracked candidate is gx-03 (Phase 2) for onychomycosis.
What is Turn Therapeutics Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Turn Therapeutics Inc. has approximately 20.7 months of cash runway.
What is Turn Therapeutics Inc.'s market capitalization?
Turn Therapeutics Inc.'s market capitalization is approximately $191.2M.
Who is the CEO of Turn Therapeutics Inc.?
Mr. Bradley E. Burnam is the chief executive officer of Turn Therapeutics Inc. (TTRX).
Get the full picture on Turn Therapeutics Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.